Latest Trial Data Shows Potential of BAN2401 in Preventing Cognitive Decline in Early Alzheimer’s

Latest Trial Data Shows Potential of BAN2401 in Preventing Cognitive Decline in Early Alzheimer’s
The latest data from a Phase 2 trial (study 201) demonstrates that BAN2401 can slow cognitive decline, providing additional evidence of its potential as a disease-modifying therapy for Alzheimer's disease, according to Eisai and Biogen, which are jointly developing the investigative therapy. BAN2401 is an engineered antibody designed to specifically bind and neutralize toxic amyloid aggregates, which are well-known contributors of the neurodegenerative process in Alzheimer’s disease. The Phase 2 (study 201) trial (NCT01767311) enrolled 856 patients with early Alzheimer’s disease who had amyloid protein accumulation in the brain. Participants were randomly assigned to receive one of five treatment regimens with the investigative antibody — 2.5 mg, 5 mg, or 10 mg per kg body weight once every two weeks; 5 or 10 mg per kg body weight once a month; or a placebo. The results, announced by Eisai and Biogen, revealed that patients treated with the 10 mg/kg every two weeks regimen for 18 months — the highest tested dose of BAN2401 — had a 30% slower cognitive decline compared to placebo-treated patients. This positive effect, determined by the Alzheimer's Disease Composite Score (ADCOMS), was first noted as early as six months into treatment. Evaluation with the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) and the Clinical Dementia Rating Scale–Sum of Boxes
Subscribe or to access all post and page content.